|
Intercept plant Finanzierung
ir.interceptpharma.com/news-releases/...proposed-offerings-200
www.fool.com/investing/2019/06/30/...icals-vs-cv-science.aspx
Zahlen für 2019
"The FDA has set a Prescription Drug User Fee Act(“PDUFA”) target action date of June 26, 2020for the completion of its review of our NDA seeking approval of OCA for liver fibrosis due to NASH. As a result of the uncertainties relating to the launch of OCA in liver fibrosis due to NASH and their potential impact on our 2020 financial performance, we are not providing 2020 net sales guidance."
ir.interceptpharma.com/news-releases/...uarter-and-full-year-0
Sitzung des Beratungsausschusses wird verschoben
Die FDA hat zusätzliche Daten angefordert.
ir.interceptpharma.com/news-releases/...es-regulatory-update-0
CRL für OCA (in NASH)
Zum Glück hab ich das geahnt, und bin letzte Woche zu 82$ mit Gewinn raus.
ir.interceptpharma.com/news-releases/...-fda-obeticholic-acid
Intercept entlässt 25% seiner Mitarbeiter
xconomy.com/new-york/2020/09/01/...a-slashes-headcount-by-25/
|
Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
7 | 218 | Intercept Pharmaceuticals Inc | rokrockt | Vassago | 26.09.23 16:05 |